老年局部进展期直肠癌化疗不耐受者的短程放疗:SOFT研究
SOFT研究纳入141例≥70岁、不适合化疗的局部进展期直肠癌(LARC)患者,在意大利11个中心接受短程放疗(SCRT,25 Gy/5次)后延迟手术。降期率61.7%,R0切除率93.6%,病理完全缓解(pCR)率5.7%,中位随访70.5个月时中位无复发生存(RFS)、总生存(OS)和癌症特异性生存(CSS)分别为31.5、40.5和41.5个月,术后严重并发症发生率23.4%,死亡率2.8%。
要点
- ≥70岁不适合化疗的LARC患者接受SCRT后延迟手术,降期率61.7%,R0切除率93.6%。
- 中位随访70.5个月,中位RFS 31.5个月、OS 40.5个月、CSS 41.5个月。
- 术后严重并发症发生率23.4%,死亡率2.8%。
核心结论
- SCRT可作为不适合化疗的老年LARC患者替代长期放化疗的可行选择,疗效较好、毒性有限且死亡率低。
研究设计与样本
- 多中心研究,2019年2月至2024年4月意大利11个中心纳入141例≥70岁(中位79岁,范围70-91)、不适合化疗的II-III期直肠腺癌患者。
- 所有患者接受SCRT(5次每日5 Gy,总剂量25 Gy)后延迟手术(不早于治疗结束后6周)。
主要发现
- 降期87例(61.7%),SCRT后术前完全影像学缓解10例(7.1%),部分缓解77例(54.6%)。
- 全部患者接受延迟手术,R0切除率93.6%,病理完全缓解(pCR)8例(5.7%)。
- 中位随访70.5个月,中位RFS 31.5个月、OS 40.5个月、CSS 41.5个月。
- 术后严重并发症发生率23.4%,死亡率2.8%。
临床怎么用
- 对≥70岁、不适合化疗的局部进展期直肠癌患者,可考虑SCRT后延迟手术作为治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of locally advanced rectal cancer (LARC) in older patients is not sufficiently standardized in international guidelines. Short-course radiotherapy (SCRT) followed by delayed surgery has emerged as a promising therapeutic option for these patients, offering potential benefits in terms of reduced treatment time and toxicity, along with improved convenience. MATERIALS AND METHODS: From February 2019 to April 2024, a total of 141 older patients aged ≥ 70 years [median age = 79 (range, 70-91)], unfit for chemotherapy and with LARC (stage II-III) adenocarcinoma, underwent SCRT (5 daily fractions of 5 Gy each for a total dose of 25 Gy) followed by delayed surgery (no earlier than 6 weeks after the end of treatment). The study was conducted at 11 centers in Italy. Down-staging rates, relapse-free survival (RFS), overall survival (OS), cancer-specific survival (CSS), safety, and mortality were analyzed. RESULTS: Down-staging occurred in 87 cases (61.7 %). Complete radiological responses after SCRT and before surgery were reported in 10 patients (7.1 %), while partial responses were reported in 77 (54.6 %) cases. All patients underwent delayed surgery. The R0 resection rate was 93.6 %. Eight patients (5.7 %) had a pathological complete response (pCR). At a follow-up of 70.5 months, the median RFS, OS and CSS were 31.5, 40.5 and 41.5 months, respectively. Post-operative severe morbidity was 23.4 %, and mortality was 2.8 %. CONCLUSIONS: Overall, SCRT offers a viable alternative to conventional long-term radiotherapy plus chemotherapy in older patients with LARC, with favorable results in terms of efficacy, limited toxicity and low mortality.
引用
- Rosati G, Stefano A, Restivo A, et al. SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY. Radiother Oncol. 2025. PMID: 41429719. doi:10.1016/j.radonc.2025.111218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。